MABQI is a biotech company specializing in the discovery and development of next-generation innovative antibodies and immunotherapies.

Its LiteMab© Antibody Discovery Studio integrates a suite of synthetic fully human libraries with an AI-powered display platform. The innovative LiteMab Sense platform specializes in pH-sensitive binders, optimizing therapeutic safety and efficacy by activating selectively in tumor or acidic microenvironments.

MABQI is advancing a targeted oncology pipeline leveraging its LiteMab© platform, featuring first-in-class and best-in-class highly developable antibodies- some with pH-sensitive features—spanning antibody-drug conjugates (ADCs), multispecific antibodies, and T-cell engagers to address critical unmet needs in solid and hematological tumors.

MABQI also welcomes research collaborations with biopharma partners on antibody discovery and maturation programs.